Patents Assigned to ULTRAHUMAN FOUR LIMITED
  • Method of using anti-CD47 antibody molecules
    Patent number: 11370840
    Abstract: The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to CD47 (Cluster of Differentiation 47, also known as integrin associated protein [IAP]). In aspects of the invention, the anti-CD47 antibody molecules and antigen-binding portions thereof specifically bind to human CD47 and cynomolgus monkey CD47. Medical uses of the anti-CD47 antibody molecules and antigen-binding portions of the invention are disclosed. The anti-CD47 antibody molecules and antigen-binding portions of the invention represent modified and optimised binding molecules compared with a VxP037 murine/humanized anti-CD47 antibody described in WO2014/093678A2.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: June 28, 2022
    Assignee: ULTRAHUMAN FOUR LIMITED
    Inventor: William James Jonathan Finlay
  • Anti-CD47 antibody molecules
    Patent number: 10683350
    Abstract: The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to CD47 (Cluster of Differentiation 47, also known as integrin associated protein [IAP]). In aspects of the invention, the anti-CD47 antibody molecules and antigen-binding portions thereof specifically bind to human CD47 and cynomolgus monkey CD47. Medical uses of the anti-CD47 antibody molecules and antigen-binding portions of the invention are disclosed. The anti-CD47 antibody molecules and antigen-binding portions of the invention represent modified and optimised binding molecules compared with a VxP037 murine/humanized anti-CD47 antibody described in WO2014/093678A2.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: June 16, 2020
    Assignee: ULTRAHUMAN FOUR LIMITED
    Inventor: William James Jonathan Finlay